IceCure Medical (ICCM)
(Delayed Data from NSDQ)
$1.07 USD
+0.01 (0.94%)
Updated May 31, 2024 03:54 PM ET
After-Market: $1.08 +0.01 (0.93%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ICCM 1.07 +0.01(0.94%)
Will ICCM be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ICCM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ICCM
Doximity (DOCS) Q4 Earnings and Revenues Surpass Estimates
ReWalk Robotics (LFWD) Reports Q1 Loss, Misses Revenue Estimates
ICCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Oncology Institute, Inc. (TOI) Reports Q1 Loss, Lags Revenue Estimates
DocGo Inc. (DCGO) Matches Q1 Earnings Estimates
Ascend Wellness Holdings, Inc. (AAWH) Reports Q1 Loss, Tops Revenue Estimates
Other News for ICCM
Icecure Medical: Strong Sales Growth and Promising Regulatory Prospects Underpin Buy Rating
ICCM Stock Earnings: Icecure Medical Meets EPS, Misses Revenue for Q1 2024
IceCure Medical Sees Strong Q1 Growth, Awaits FDA Nod
IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024
IceCure Medical GAAP EPS of -$0.08 in-line, revenue of $0.74M misses by $0.14M